Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review

BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare malignancy. The management of metastatic or unresectable UTUC is mainly based on evidence extrapolated from histologically homologous bladder cancer, including platinum-based chemotherapy and immune checkpoint inhibitor alone, whereas UTU...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Tianyuan, Guo, Hanxu, Xie, Jun, He, Yanyan, Che, Jianping, Peng, Bo, Yang, Bin, Yao, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328386/
https://www.ncbi.nlm.nih.gov/pubmed/37427135
http://dx.doi.org/10.3389/fonc.2023.1119343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328386/
https://www.ncbi.nlm.nih.gov/pubmed/37427135
http://dx.doi.org/10.3389/fonc.2023.1119343

Ejemplares similares